Cefuroxime is a new semisynthetic parenteral cephalosporin developed by Glaxo Research Ltd. Preliminary studies have indicated that the a-methoximino group at position 7 of cefuroxime gives resistance to ,3-lactamase. It has wide activity against Gram negative bacilli including Enterobacter and many strains of indole positive Proteus spp., It is also highly active against Ha?mophilus influenza, and Neisseria gonorrhea.
Cefuroxime also has a metabolically stable carbamoyloxymethyl ester at position 3, so that it gives good serum levels and there is almost complete recovery of cefuroxime unchanged in the urine. Studies on animal toxicity have also reported that cefuroxime appears to be of very low toxicity and in particular to have no toxic action on the kidney.
Our preliminary clinical studies with cefuroxime have been performed on patients at 25 Japanese hospitals between March and June 1977. The cases of urinary tract infection in this study programme will be reported separately by Professor Naide in this symposium (p 166).
Most of the 70 patients reported here were suffering from respiratory tract infection but cases of septicamia and biliary tract infection were also included ( Table 1) . The age range covered was 15-89 years with more than one-half of the patients over 60 years.
The daily doses and administration routes of cefuroxime are given in detail in Table 2 . Two patients were dosed once daily, 46 twice daily, Table 3 . The clinical effectiveness was recorded as excellent when all the clinical symptoms disappeared rapidly following cefuroxime administration; good when the clinical symptoms showed considerable improvement; fair when the clinical symptoms improved gradually or if the symptoms reappeared after stopping cefuroxime although they had improved rapidly following treatment, and poor when no clinical response was obtained.
In the 5 cases of septicmmia, 2 cases showed a good and 1 showed a fair response clinically.
In 57 patients with respiratory tract infections, the clinical effectiveness was not assessable in 2 cases of mycoplasma infection and in I case in which cefuroxime administration had to be discontinued because of the incidence of side effects within a day. Of the 54 remaining cases, 10 showed excellent, 26 showed good and 7 showed fair responses, an overall effectiveness ratio of 66.7 %.
Of the 5 cases of biliary tract infection, I case showed excellent and 4 showed good responses. The effectiveness ratio therefore was 100%. A good response was also observed in all 3 cases of lymphadenitis, sinusitis and acute colitis.
In summary, out of a total of 70 cases, 3 were unassessable, 11 showed excellent, 35 showed good and 8 showed fair response; an overall effectiveness ratio of 68.7 %.
The relationship between clinical effectiveness, causative organisms and daily doses with 5 cases of septicemia is given in Tables 4 and 5. All these 5 patients with septicxemia were compromised hosts with underlying diseases such as cancer, aplastic anemia, uremia or systemic lupus erythematosis. Causative organisms eradicated after cefuroxime administration were an anaerobic Gram positive bacilli and Escherichia coli. The 3 patients concerned received a daily dose of cefuroxime of 750 mg twice daily in 2 cases and 1500 mg three times daily in I case. Details of 57 cases of respiratory tract infections are shown in Table 6 . Out of 29 cases of pneumonia (the largest group) 7 cases were excellent, 13 were rated good and 5 were rated fair. Exclud-ing 2 cases of mycoplasma pneumonia, the overall effectiveness ratio was 74.1 %.
Cefuroxime exhibited poor clinical responses in lung abscess and infected lung cancer. With the other respiratory tract infections, the efficacy of cefuroxime was 67-100%. Table 7 shows the relationship between causative organisms and clinical effectiveness with respiratory tract infections. It was difficult to identify the causative organisms and in 29 cases (that is, in half of the subjects) they remained unknown. However, the bacteriological effectiveness of cefuroxime was observed in those cases in which the causative organisms could be identified. The relationship between daily doses and clinical effectiveness with respiratory tract infections is shown in Table 8 . Based upon the change in serum levels following cefuroxime administration, dosage 3 times daily or more was thought to be more effective than twice daily. However, the clinical effectiveness after doses of 750 mg or 1500 mg twice daily proved equal or superior to that obtained with 4 times daily dosing. These results were probably due to cefuroxime being administered twice daily with milder infections and by 3-4 times daily with severe infections. At all events, no clear dose-response relationship was observed with the clinical effectiveness of cefuroxime.
Among 5 cases of biliary tract infections, 4 had acute cholecystitis complicated with cholelithiasis and 1 had cholangitis. In all cases no causative organisms could be identified and the bacteriological effectiveness remained unknown. The relationship between daily dose and clinical effectiveness of cefuroxime is shown in Table 9 . All 3 patients who received cefuroxime 750 mg twice or three times daily showed good responses. With 2 patients who received cefuroxime 1500 mg three times daily, it was rated excellent in one and good in the other. The side effects observed in 70 patients following cefuroxime administration are shown in Table 10 . Five patients of 17 who received i.m. injection of cefuroxime (29.4%) complained of pain at the injection site. The other side effects were fever, rash, fever with lymphadenopathy, eosinophilia and elevated SGOT, SGPT and ALP, eosinophilia and elevated serum alkaline phosphatase.
Patients showing these side effects (excepting the local pain after i.m. injection) were 8 in total, 1 1.4 % of all subjects studied.
it is difficult to determine appropriate daily doses of and indications for cefuroxime from results obtained so far on such a small number of patients. However, it is certain that cefuroxime was effective against, these infections and that the frequency of side effects was low with no severe symptoms. We intend to perform further investigations on a large number of patients with a greater variety of infections.
